Your browser doesn't support javascript.
loading
The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder.
Takahashi, Shinji; Ohmiya, Makoto; Honda, Sokichi; Ni, Keni.
Affiliation
  • Takahashi S; Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
  • Ohmiya M; Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
  • Honda S; Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
  • Ni K; Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
PLoS One ; 13(11): e0207750, 2018.
Article in En | MEDLINE | ID: mdl-30462746
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Attention Deficit Disorder with Hyperactivity / Triazines / Potassium Channel Blockers / Ether-A-Go-Go Potassium Channels / Nerve Tissue Proteins Type of study: Prognostic_studies Limits: Animals Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Attention Deficit Disorder with Hyperactivity / Triazines / Potassium Channel Blockers / Ether-A-Go-Go Potassium Channels / Nerve Tissue Proteins Type of study: Prognostic_studies Limits: Animals Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2018 Document type: Article Affiliation country: Country of publication: